LENZ Therapeutics
LENZ
78 hedge funds and large institutions have $445M invested in LENZ Therapeutics in 2024 Q3 according to their latest regulatory filings, with 22 funds opening new positions, 20 increasing their positions, 17 reducing their positions, and 9 closing their positions.
144% more first-time investments, than exits
New positions opened: 22 | Existing positions closed: 9
36% more capital invested
Capital invested by funds: $327M → $445M (+$118M)
20% more funds holding
Funds holding: 65 → 78 (+13)
18% more repeat investments, than reductions
Existing positions increased: 20 | Existing positions reduced: 17
0% more funds holding in top 10
Funds holding in top 10: 4 → 4 (0)
5.95% less ownership
Funds ownership: 74.08% → 68.13% (-6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$9.96M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.61M |
| 3 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
+$3.09M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
+$2.38M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$1.82M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
EC
EcoR1 Capital
San Francisco,
California
|
-$19.4M |
| 2 |
Alyeska Investment Group
Chicago,
Illinois
|
-$4.43M |
| 3 |
SAM
Sectoral Asset Management
Montreal,
Quebec, Canada
|
-$2.38M |
| 4 |
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University
Redwood City,
California
|
-$1.74M |
| 5 |
PM
Prosight Management
Dallas,
Texas
|
-$1.03M |
LENZ Hedge Fund Activity: Q3 2024 in Review
78 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in LENZ Therapeutics (LENZ) for Q3 2024, worth a combined $445M — up 36% from $327M a quarter earlier.
Buyers outnumbered sellers: 22 funds opened new LENZ positions and 9 closed out — a net gain of 13 holders — while 20 added to existing stakes and 17 trimmed.
The largest buyer was T. Rowe Price Associates, opening a new position worth an estimated $9.96M. The largest seller was EcoR1 Capital, cutting an estimated $19.4M.
- 78 institutional investors held LENZ Therapeutics (LENZ) as of Q3 2024, up from 65 in Q2 2024.
- Funds reported $445M of LENZ Therapeutics stock for Q3 2024, up 36% quarter-over-quarter.
- 22 funds opened new LENZ Therapeutics positions in Q3 2024 and 9 closed out, a net change of +13 holders.
- The largest LENZ Therapeutics buyer in Q3 2024 was T. Rowe Price Associates, an estimated $9.96M added.
- The largest LENZ Therapeutics seller in Q3 2024 was EcoR1 Capital, an estimated $19.4M sold.
Based on aggregated 13F filings for Q3 2024.